Return to Home Page

Achievements is a 501(c)(3) non-profit organization. It investigates and facilitates the availability of immune system modulating therapies for patients with chronic conditions such as Allergies, Asthma, Cancer, Chronic Fatigue Syndrome, Colds, Fibromyalgia, Flu, Hay Fever, Hepatitis, Infections, Lyme Disease, Lymphoma and others. focuses on immunotherapeutic compounds that fight disease by enhancing the immune system rather than directly attacking the disease (and potentially the patient).

What has this little foundation done?

  1. treated the first U.S. patient in the first FDA-endorsed clinical trial of this new non-toxic, paradigm-breaking treatment for humans. The U.S. studies were part of a larger trial that started in Canada. Fox News returned to report on the Canadian (1999) and U.S. studies (2000). presented these findings at the American Society of Hematology (2001).
  2. was one of the first organizations to respond to the NIH "State-of- the-Science" Statement seeking new therapies for fatigue in Cancer patients.
  3. presented findings from studies of another nontoxic immunotherapeutic at the First International Conference on Whole Person Healing and the International Complementary and Integrative Medicine conference.

Details on Work to Date

Human Trials: has brought beta-alethine human trials to the U.S. In Canada, people with cancer and functional immune systems, treated with beta-alethine, have had shrinkage of cancers without any side effects. Shrinkage was observed even with large cancers in people who have previously failed chemotherapy.

Dr. Wilson Miller, Head of the McGill University Clinical Research Unit and Principal Investigator says:

"To actually have noticeable responses is somewhat unusual at this early time and obviously quite encouraging." (Fox News report, 1999)

Later, in a conference presentation:

"Data to date indicate Beta LT™ at this dose is non-toxic, increases surface TNF, and can have anti-lymphoma effects." - August 2000

Animal Findings: first donated beta-alethine to veterinarians for use in pets. Success has been observed in treating some pets with myeloma, lymphoma, lymphosarcoma, and breast cancer. The benefit has even been dramatic in some. No animals have had toxic side effects even those receiving one million times more than the standard human dose.

Award to Dr. Carol Pontzer:

Dr. Carol Pontzer was awarded the first "Non-toxic Immune Treatment Cancer Award" for her work at the University of Maryland. She created a second generation interferon (antiviral protein) using recombinant DNA technology. This molecule is believed to be less toxic than previous interferons. Additional funds are necessary for clinical testing. Subsequent to the award, NIH has sponsored gene expression work on this molecule.

Ongoing and New Studies did initial evaluation of one compound as a method to improve the 'quality of life' (QOL) in a type of lymphoma called Waldenstrom's Macroglobulinemia.

Synonyms and alternate names

Beta-Alethine is sometimes called Beta LT™ or Beta-alanyl Cysteamine. is a 501(c)(3) non-profit organization.

Donate now!